Group One Trading
ACRS icon

Group One Trading’s Aclaris Therapeutics ACRS Stock Holding History

Group One Trading’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,433
Closed -$42K – 7514
2025
Q4 		$37.4K Buy
12,433
+10,685
+611% +$27K ﹤0.01% 5833
2025
Q3 		$3.32K Sell
1,748
-700
-29% -$1.22K ﹤0.01% 7734
2025
Q2 		$3.48K Buy
+2,448
New +$3.31K ﹤0.01% 7234
2024
Q3 		– Sell
-5,549
Closed -$6.8K – 6554
2024
Q2 		$6.1K Sell
5,549
-128,282
-96% -$151K ﹤0.01% 5872
2024
Q1 		$166K Buy
133,831
+56,630
+73% +$67.5K ﹤0.01% 3721
2023
Q4 		$81.1K Buy
77,201
+8,911
+13% +$27.2K ﹤0.01% 4641
2023
Q3 		$468K Buy
68,290
+18,259
+36% +$156K ﹤0.01% 2980
2023
Q2 		$519K Sell
50,031
-41,395
-45% -$375K ﹤0.01% 2978
2023
Q1 		$740K Buy
+91,426
New +$1.16M ﹤0.01% 2400
2022
Q4 		– Sell
-457
Closed -$7.35K – 7139
2022
Q3 		$7K Sell
457
-1,999
-81% -$31.5K ﹤0.01% 6679
2022
Q2 		$34K Sell
2,456
-256
-9% -$3.59K ﹤0.01% 5880
2022
Q1 		$47K Sell
2,712
-707
-21% -$9.64K ﹤0.01% 6129
2021
Q4 		$50K Sell
3,419
-2,623
-43% -$39.7K ﹤0.01% 6339
2021
Q3 		$109K Buy
6,042
+4,273
+242% +$68.5K ﹤0.01% 5829
2021
Q2 		$31K Sell
1,769
-14,380
-89% -$327K ﹤0.01% 6933
2021
Q1 		$407K Sell
16,149
-31,484
-66% -$616K ﹤0.01% 4285
2020
Q4 		$308K Buy
47,633
+40,033
+527% +$169K ﹤0.01% 3714
2020
Q3 		$20K Buy
7,600
+5,100
+204% +$11.4K ﹤0.01% 5116
2020
Q2 		$4K Buy
+2,500
New +$3.35K ﹤0.01% 5400
2020
Q1 		– Sell
-11,451
Closed -$15.6K – 5170
2019
Q4 		$22K Buy
11,451
+8,954
+359% +$14.8K ﹤0.01% 4331
2019
Q3 		$3K Sell
2,497
-16,085
-87% -$22.8K ﹤0.01% 4843
2019
Q2 		$41K Buy
18,582
+17,732
+2,086% +$96.7K ﹤0.01% 3867
2019
Q1 		$5K Buy
+850
New +$5.63K ﹤0.01% 4427

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Group One Trading's ACRS Position: Q1 2026 in Review

Group One Trading sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 12,433 shares — an estimated $42K sold.

Group One Trading first reported a position in ACRS in Q1 2019 and held it in 23 quarters. The position peaked at $740K in Q1 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Group One Trading reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 12,433 Aclaris Therapeutics shares in Q1 2026, an estimated $42K.
  • Group One Trading first reported a position in Aclaris Therapeutics in Q1 2019 and held it in 23 quarters.
  • Group One Trading's Aclaris Therapeutics position peaked at $740K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.